Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the pending start of its upcoming human nicotine study NIC-H22-1. Through the study, Lexaria expects to evidence that processing purified nicotine with its patented drug delivery technology, DehydraTECH(TM), leads to enhanced oral-tissue absorption and reduced negative experiences. NIC-H22-1, a minimum 36-person human pharmacokinetic (“PK”) randomized, double blinded, cross-over study, will compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. The primary objective of the study is data collection from blood samples that will evidence Tmax, Cmax and AUC. Secondary objectives include extensive subjective evaluations related to throat burn, user experience and more. Nicotine test article ingredient manufacturing and DehydraTECH processing have been completed, and the third-party pouch manufacturing company has received those processed materials for filling and packaging. Independent Review Board approval and subsequent human dosing will be the next two major steps in the study.
To view the full press release, visit https://ibn.fm/DIO98
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment